Federated Hermes’s Verrica Pharmaceuticals VRCA Stock Holding History

Federated Hermes’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-24	Closed	-$652	–	2274
2022 Q4	$652	Buy	+24	New	+$640	﹤0.01%	2073
2022 Q3	–	Sell	-93	Closed	-$2K	–	2252
2022 Q2	$2K	Buy	+93	New	+$4.67K	﹤0.01%	2003
2020 Q2	–	Sell	-4	Closed	-$1K	–	2383
2020 Q1	$1K	Sell	4 -1,728	-100%	-$227K	﹤0.01%	2159
2019 Q4	$275K	Buy	+1,732	New	+$256K	﹤0.01%	1553

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Federated Hermes's VRCA Position: Q1 2023 in Review

Federated Hermes sold out of Verrica Pharmaceuticals (VRCA) in Q1 2023, closing a stake of 24 shares — an estimated $652 sold.

Federated Hermes first reported a position in VRCA in Q4 2019 and held it in 4 quarters. The position peaked at $275K in Q4 2019. 59 funds tracked by Wall St. Rank hold VRCA as of Q1 2023.

Federated Hermes reported no remaining Verrica Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Federated Hermes sold 24 Verrica Pharmaceuticals shares in Q1 2023, an estimated $652.
Federated Hermes first reported a position in Verrica Pharmaceuticals in Q4 2019 and held it in 4 quarters.
Federated Hermes's Verrica Pharmaceuticals position peaked at $275K in Q4 2019.
59 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.